Definiens and Metamark Genetics announced a multi-year agreement covering use of the Definiens image analysis solution for the ProMark.
ProMark is a multiplex immunofluorescence test that integrates Definiens’ core image analysis platform, Cognition Network Technology.
It is to automatically classify prostate tumor “regions of interest” and quantify novel proteomic markers expressed in prostate biopsies.
Definiens’ software platform will be used to support Metamark’s fully automated analysis of clinical prostate cancer biopsies.
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity